The article discusses the authors' views about the monitoring and assessment of medical countermeasures (MCMs) as part of the U.S. government's response to a public health emergency, and it mentions the efficacy and safety of MCMs which include drugs and medical products. The infrastructure for MCM administration is examined, along with the American Food and Drug Administration's drug and medical product approval processes.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados